| Date | Time | Source | Announcement |
|---|---|---|---|
| 03 May 2022 | 07:00 AM | Notice of Results | |
| 06 Apr 2022 | 07:00 AM | Director Appointment | |
| 23 Mar 2022 | 07:00 AM | Indiana University Medical School collaboration | |
| 15 Mar 2022 | 07:00 AM | Lipid inCode pilot | |
| 21 Feb 2022 | 01:17 PM | Confirmation of board appointment | |
| 08 Feb 2022 | 07:00 AM | Positive results for Lipid inCode in NHS study | |
| 21 Jan 2022 | 07:00 AM | Proposed independent directorate appointment | |
| 10 Jan 2022 | 07:00 AM | FDA Pre-Submission for Cardio inCode-SCORE | |
| 29 Nov 2021 | 07:00 AM | Directorate Change | |
| 25 Nov 2021 | 07:00 AM | Trading update | |
| 17 Sep 2021 | 10:38 AM | Grant of Share Options and PDMR dealing | |
| 16 Sep 2021 | 07:00 AM | Half-year Report | |
| 10 Sep 2021 | 07:00 AM | Holding(s) in Company | |
| 02 Sep 2021 | 07:00 AM | Notice of Results | |
| 27 Jul 2021 | 09:27 AM | Holding(s) in Company | |
| 26 Jul 2021 | 07:00 AM | Positive Thrombo inCode clinical results | |
| 23 Jul 2021 | 04:04 PM | Holding(s) in Company | |
| 23 Jul 2021 | 09:53 AM | Holding(s) in Company | |
| 22 Jul 2021 | 07:00 AM | Admission to trading on AIM & First Day of Dealing |
GENinCode is a predictive genetics biotechnology company that does genomic testing, AI bioinformatics and clinical algorithms to assess and prevent cardiovascular disease, thrombosis, familial hypercholesterolemia and ovarian cancer.
GENinCode share price is listed in London under the ticker GENI.